Even if safety data is not aggregated across clinical trials it is reported out with each trial. I find it disingenuous by the FDA to suggest the drug is not necessarily safe after a full suite of HIV trials through phase 3, or to borrow an observation by Jay Lalezari related to the mild/moderate covid19 trial “there were fewer side effects in the drug arm than placebo; in all my experience doing clinical trials I have never seen this…”

Your point is well taken and the aggregated safety data should settle it and hopefully light a fuse somewhere where something explosive happens next.